SAB Biotherapeutics

Advancements Towards A Treatment For Ebola

Aug 24, 2018
Adria Botella

Eddie Sulivan, SAB Biotherapeutics president and CEO, joined Innovation to discuss the recent advancements made by his company.

SAB Biotherapeutics announced its anti-Ebola immunotherapy provided 100% protection against a lethal dose of the Ebola virus in a recent animal study published in The Journal of Infectious Diseases.

The Ebola virus disease is a severe, often fatal illness in humans. There is currently no licensed treatment proven to neutralize the virus. 

Lori Walsh

In The Moment ... June 8, 2018 Show 354 Hour 2

The USD Discovery District has its first anchor tenant - SAB Biotherapeutics, Inc.  SAB president, CEO and co-founder Eddie Sullivan talks about being the first tenant and shares his goals for the first project.  He's joined by Rich Naser, president of the USD Discovery District.

Melissa Ullerich

Ag Innovation is the focus of a panel conversation during the Governor’s Ag Summit in Aberdeen. Other topics include animal health, economics and succession planning.  The annual event brings awareness to the economic potential of agriculture in South Dakota.

Jerry Pommer is the Chief Compliance Officer of SAb Biotherapeutics.  He says the company's research project, DiversitAb, uses genetically-designed cattle to produce human antibodies against global diseases.

SAB Biotherapeutics, Inc.

Eddie Sullivan is the President, CEO and Co-Founder of SAB Biotherapeutics, Inc. based in Sioux Falls. The biopharmaceutical company leads the science and manufacturing of polyclonal antibody therapies. Eddie Sullivan has been named chair of the food and agriculture section governing board for the Biotechnology Innovation Organization or Bio. It’s the industry’s largest international trade association.